Summary Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone. None of the 4 patients with intact testes responded, although 3 did so subsequently to tamoxifen. The previously orchidetomised patient responded to amminoglutethimide for 14 months. Oestrone and oestradiol were suppressed by AG in all patients, but not to the levels achieved by orchidectomy. AG produced substantial further oestrogen suppression in the orchidectomised patient and should only be used after orchidectomy.
Breast cancer in males is an uncommon disease. It accounts for 1 % of all breast cancers and is frequently sensitive to hormone manipulation (Ribeiro, 1985) . Breast cancer in men presents at a more advanced stage and in older age groups compared with women, but when matched for these prognostic variables, survival is similar (Scheike, 1982) . Because of these clinical features, systemic endocrine therapy is commonly combined with local treatment, castration being a standard first line endocrine approach.
Recently, aminoglutethimide has been shown to be effective in postmenopausal women with breast cancer, the main mechanism of action being inhibition of the peripheral conversion of androgens to oestrogens by aromatase (Harris et al., 1982a; 1983a) . In men, three quarters of oestradiol produced results from peripheral aromatisation of testosterone (Epstein et al., 1966; Longcope et al., 1969; Wu et al., 1982) . Thus aminoglutethimide could potentially be useful either to avoid castration or as a second line endocrine therapy to suppress residual oestrogen production via androgens from the adrenal after castration. oestradiol, testosterone and A4 androstenedione by previously described assays (Harris et al., 1982a,b; 1983a, b) .
Tumour response was assessed by standard UICC criteria (Hayward et al., 1977) .
Results
Clinical responses to aminoglutethimide and hydrocortisone The pretreatment characteristics are shown in Table I 48% (Patel et al., 1984; Kraybill et al., 1981 Ribeiro, 1983) , so antioestrogen effects are important. Stilboestrol has been used as a first-line therapy, but this will also suppress androgens (Ribeiro, 1976 (Patel et al., 1984; Meyskens et al., 1976) . Corticosteroids alone produced a response of 43% after orchidectomy, presumably by suppressing residual adrenal androgen production and hence removing a source of oestrogens (Kantarjian et al., 1983) .
The endocrine data show that aminoglutethimide plus hydrocortisone suppresses peripheral oestrone and oestradiol levels.
The lower dose of aminoglutethimide plus hydrocortisone produced as much oestrone and oestradiol suppression as the conventional dose plus hydrocortisone. A similar effect of conventional doses has been shown in normal males (Santen et al., 1979) . However, this suppression was inadequate to produce a therapeutic response. Basal oestradiol levels in our series were in the same range as reported by Nirmul et al. (1982) . The patients were not intrinsically resistant to endocrine therapy, since 3 out of 4 responded to tamoxifen. Aminoglutethimide did not suppress oestrogens to the level obtained by orchidectomy, thus suggesting a doseresponse effect.
In the orchidectomised patient, a response was obtained and residual oestrogen levels were suppressed by more than 50%. There is one previous case of effective therapy with aminoglutethimide (Patel et al., 1984) after orchidectomy.
Although these results are only on a small number of patients, they suggest that aminoglutethimide plus hydrocortisone should not be used -W A -A, as a first-line therapy, that they are worth using as a second line therapy after orchidectomy, and that adequate oestrogen rather than androgen suppression is important.
The lower dose of aminoglutethimide may be as effective as higher, more toxic doses, but this will require further evaluation. The effectiveness of tamoxifen in patients who had not been orchidectomised suggests this should be first-line therapy in such patients.
